Our findings suggest [18F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to be a weak tau drug, and off-target nonspecific meninges binding maybe due to the primary aromatic amine group in [18F]MK-6240. Here, MAPT is linked to Alzheimer disease.